 REDWOOD CITY, Calif., Dec. 08, 2021 GLOBE NEWSWIRE -- Jasper Therapeutics, Inc. NASDAQ: JSPR, a biotechnology company focused on hematopoietic cell transplant therapies, today announced that data on JSP191 showing long-term benefits of hematopoietic stem cells HSC engraftment following targeted single-agent JSP191 conditioning in the treatment of severe combined immunodeficiency SCID will be presented at the 2021 American Society of Hematology ASH Annual Meeting. 